TIDMAMC

RNS Number : 5605I

Amur Minerals Corporation

08 August 2023

8 August 2023

AMUR MINERALS CORPORATION

(AIM: AMC)

Cessation of discussions with Ascent Resources plc

Amur Minerals Corporation ("Amur" or the "Company") notifies that further to the Company's announcement of 2 June 2023, discussions with Ascent Resources plc ("Ascent") regarding a non-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent, have ceased.

 
 Company            Nomad and Broker        Public Relations 
  Amur Minerals      S.P. Angel Corporate    BlytheRay 
  Corp.              Finance LLP 
 Robin Young CEO    Richard Morrison        Megan Ray 
                     Adam Cowl               Tim Blythe 
 +44 (0) 7981 126                           +44 (0) 20 7138 
  818               +44 (0) 20 3470 0470     3203 
 

For additional information on the Company, visit the Company's website, www.amurminerals.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPUGPRUPWGQM

(END) Dow Jones Newswires

August 08, 2023 02:00 ET (06:00 GMT)

Crism Therapeutics (AQSE:AMC.GB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Crism Therapeutics.
Crism Therapeutics (AQSE:AMC.GB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Crism Therapeutics.